Hiroki Komatsuda

Assistant Professor

Asahikawa Medical University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hiroki Komatsuda is an Assistant Professor at Asahikawa Medical University, Japan. His research focuses on immunotherapy for various cancers, with recent articles addressing topics such as the role of ROR1 in head and neck squamous cell carcinoma and the efficacy of PD-1 inhibitors in salivary gland carcinoma. He has explored comparative surgical outcomes and developed insights into immunological effects in cancer treatment.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Miki Takahara

Asahikawa Medical University

JAPAN

View details

Hisataka Ominato

Asahikawa Medical University

JAPAN

View details

Takayuki Ohkuri

JAPAN

View details

Takumi Kumai

Assistant Professor

Asahikawa Medical University

JAPAN

View details

Ryosuke Sato

Asahikawa Medical University

JAPAN

View details

Michihisa Kono

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hiroki Komatsuda

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma

Comparative outcomes of video-assisted thyroidectomy and traditional open surgery: a 5-year analysis of a single center experience

Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer

Soluble CD27 as a predictive biomarker for intra‐tumoral CD70/CD27 interaction in nasopharyngeal carcinoma

Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers

Central-part laryngectomy after laryngotracheal separation to manage pharyngocutaneous fistula: A case report and retrospective analysis of 12 cases

Mitogen‐activated protein kinase inhibition augments the T cell response against <i>HOXB7</i>‐expressing tumor through human leukocyte antigen upregulation

Harnessing Immunity to Treat Advanced Thyroid Cancer

Antitumor Peptide-Based Vaccine in the Limelight.

Concurrent chemoradiotherapy with cisplatin and docetaxel for head and neck squamous cell carcinoma

The efficacy of PD‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study

A tumor metastasis‐associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity

Collaborators (6)

Miki Takahara

Hisataka Ominato

Takayuki Ohkuri

Takumi Kumai

Ryosuke Sato

Michihisa Kono

Make your next move.